ATNX - Regeneron Reports Positive Data And Other News: The Good Bad And Ugly Of Biopharma
- Regeneron reports positive outcome for Phase 3 trial of Dupixent.
- Voyager slumps as FDA puts hold on Huntington’s disease program.
- Athenex boosts TCT-T cell therapy program with PharmaEssentia collaboration.
For further details see:
Regeneron Reports Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma